Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

(2016) Venkat Reddy et al.   DRUG DISCOVERY TODAY

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

(2015) T. R. W. Tipton et al.   BLOOD

Abstract 2460: Dissecting the in vitro and in vivo mechanism of action of obinutuzumab (GA101) in preclinical models using an immune effector-dead version of obinutuzumab

(2015) Sylvia Herter et al.   CANCER RESEARCH

Longer duration of B cell depletion is associated with better outcome

(2015) Sofia Sapeta Dias et al.   RHEUMATOLOGY

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers

(2015) L Ysebaert et al.   Blood Cancer Journal

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

(2015) Venkat Reddy et al.   Arthritis & Rheumatology

Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response

(2015) Diana G. Adlowitz et al.   PLoS One

An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial

(2014) Edward M Vital et al.   ANNALS OF THE RHEUMATIC DISEASES

Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers

(2014) E. F. Wallin et al.   BLOOD

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)

(2014) Chern Siang Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

(2014) S. Herter et al.   JOURNAL OF IMMUNOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function

(2013) E. G. Kamburova et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Multiple Lupus-AssociatedITGAMVariants Alter Mac-1 Functions on Neutrophils

(2013) Yebin Zhou et al.   ARTHRITIS AND RHEUMATISM

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

(2013) J. Golay et al.   BLOOD

Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

(2013) A. T. Vaughan et al.   BLOOD

NK cells dysfunction in systemic lupus erythematosus: relation to disease activity

(2013) Ana Henriques et al.   CLINICAL RHEUMATOLOGY

GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

(2013) Delila J. Kern et al.   LEUKEMIA & LYMPHOMA

Phagocytosis Is the Main CR3-Mediated Function Affected by the Lupus-Associated Variant of CD11b in Human Myeloid Cells

(2013) Liliane Fossati-Jimack et al.   PLoS One

B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies

(2013) Maria J Leandro   ARTHRITIS RESEARCH & THERAPY

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

(2012) A Ruyssen-Witrand et al.   ANNALS OF THE RHEUMATIC DISEASES

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

(2011) P. C. Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

(2011) W. Rigby et al.   ARTHRITIS AND RHEUMATISM

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

(2010) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Relationship between CD107a expression and cytotoxic activity

(2008) Esin Aktas et al.   CELLULAR IMMUNOLOGY